Statin, aspirin and metformin use and risk of hepatocellular carcinoma related outcomes following liver transplantation: A retrospective study

doi:10.5500/wjt.v14.i3.94914

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (61)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-6)

Sum=50

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=10

Sep 18, 2024 (publication date) through Aug 1, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Transplant. Sep 18, 2024; 14(3): 94914
Published online Sep 18, 2024. doi: 10.5500/wjt.v14.i3.94914

Table 6 Univariate and multivariate analysis for the endpoint of hepatocellular carcinoma related mortality

Variables	Univariate analysis		Multivariate analysis
Variables	Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value
Sex	0.87 (95%CI: 0.20-3.84)	0.86	0.90 (95%CI: 0.23-3.56)	0.88
Age at LT	1.02 (95%CI: 0.93-1.12)	0.68	1.05 (95%CI: 0.94-1.17)	0.36
Aetiology of liver disease
HBV	1.19 (95%CI: 0.34-4.21)	0.78
HCV	1.41 (95%CI: 0.41-4.21)	0.57
NAFLD	0.80 (95%CI: 0.16-3.90)	0.78
Statin use	0.46 (95%CI: 0.059-3.53)	0.45	0.32 (95%CI: 0.033-3.09)	0.32
Aspirin use	0.50 (95%CI: 0.10-2.40)	0.39	0.71 (95%CI: 0.14-3.73)	0.69
Metformin use	1.27 (95%CI: 0.36-4.49)	0.71	1.57 (95%CI: 0.61-4.04)	0.35
Statins, aspirin or metformin use¹	0.67 (95%CI: 0.21-2.08)	0.48	0.61 (95%CI: 0.18-2.08)	0.43
MTORi use	0.96 (95%CI: 0.35-2.65)	0.93	0.63 (95%CI: 0.26-1.49)	0.29
Pre LT co-morbidities
Diabetes	0.62 (95%CI: 0.11-3.51)	0.59
Stroke	N/A
Hypertension	0.29 (95%CI: 0.06-1.47)	0.14
Obesity	0.35 (95%CI: 0.10-1.15)	0.08	0.23 (95%CI: 0.06-0.85)	0.027
Ischaemic heart disease	N/A	N/A
Total cholesterol mmol/L	0.77 (95%CI: 0.17-3.45)	0.74
Other variables
Microvascular invasion	7.52 (95%CI: 2.22-25.47)	< 0.01	8.05 (95%CI: 2.63-24.68)	< 0.01
AFP > 100 ng/mL immediately pre-LT	2.83 (95%CI: 0.85-9.44)	0.09	3.11 (95%CI: 0.70-13.76)	0.14
Pre-LT regional treatments ≥ 3	1.58 (95%CI: 0.45-5.52)	0.48
Pre-LT size of largest lesion ≥ 3 cm	2.19 (95%CI: 0.60-7.96)	0.23
Beyond Milan	2.72 (95%CI: 0.80-9.30)	0.11
Beyond up-to-7	5.29 (95%CI: 1.55-18.13)	< 0.01	4.14 (95%CI: 1.09-15.81)	0.038
Complete response at LT	0.32 (95%CI: 0.055-1.88)	0.21

¹Multivariate analysis performed separately with the composite variable of statins, aspirin or metformin use included a priori.

N/A indicates numbers insufficient to calculate hazard ratio and P value. Hypertension: Systolic blood pressure > 140 mmHg. HBV: Hepatitis B virus; HCV: Hepatitis C virus; NAFLD: Non-alcoholic fatty liver disease; AFP: Alfa-fetoprotein; BMI: Body mass index; LT: Liver transplantation.

Citation: Chung W, Wong K, Ravindranayagam N, Tang L, Grace J, Wong D, Con D, Sinclair M, Majumdar A, Kutaiba N, Hui S, Gow P, Muralidharan V, Dobrovic A, Testro A. Statin, aspirin and metformin use and risk of hepatocellular carcinoma related outcomes following liver transplantation: A retrospective study. World J Transplant 2024; 14(3): 94914
URL: https://www.wjgnet.com/2220-3230/full/v14/i3/94914.htm
DOI: https://dx.doi.org/10.5500/wjt.v14.i3.94914